Chinese Journal of Dermatology ›› 2026, Vol. 59 ›› Issue (7): 619-625.doi: 10.35541/cjd.20250682

• Expert Commentary • Previous Articles     Next Articles

Solar urticaria: pathogenesis, current treatments, and future prospects

Chen Quan1, He Fengmei1,2, Zhou Xin1, Liang Bihua1, Zhu Huilan1   

  1. ¹Guangzhou Dermatology Hospital, Institute of Dermatology, Guangzhou Medical University, Guangzhou 510095, China; ²Guangzhou Medical University, Guangzhou 511436, China
  • Received:2025-12-03 Revised:2026-06-04 Online:2026-07-15 Published:2026-07-03
  • Contact: Chen Quan E-mail:quanchen1985@gmail.com
  • Supported by:
    Guangzhou Science and Technology Plan Project(2023A03J0942,2023A03J0943)

Abstract: 【Abstract】 Solar urticaria (SU) is a rare photosensitive skin disorder induced by ultraviolet and/or visible light radiation. Its pathological mechanisms remain unclear, primarily involving the conversion of serum and/or dermal chromophores into photoallergens after absorbing specific action spectra, subsequently inducing mast cell activation and leading to clinical manifestations such as wheals, erythema, and occasionally angioedema. The pathogenesis of SU involves abnormal chromophores and IgE, with mast cells serving as the primary effector cells. Its occurrence and development are mediated by the IgE-FcεRⅠ signaling pathway, the signal transducer and activator of transcription 3 pathway, and the non-classical opsin pathway. Clinical management strategies for SU mainly include sun protection and light avoidance, antihistamines, biologics, and photohardening therapy. This article reviews advances in the pathogenesis and treatment of SU based on current research in China and other countries.

Key words: Urticaria, Solar urticaria, Ultraviolet, Visible light, Mast cell, IgE, Omalizumab